Next Publication In:
Days: 00
Hours: 00
Minutes: 00
Seconds: 00

REVIEW ON DRUG REGULATORY AFFAIRS (DRA) AND NEW DRUG APPROVAL PROCESS

📘 Volume 11 📄 Issue 12 📅 December 2025

👤 Authors

Mr. Anurag Shivanand Jaybhaye 1 , Mr. Arshad Asif Ansari 1 , Dr. Sunil S Jaybhaye 1
1. ., Institute of Pharmacy Badnapur

📄 Abstract

Regulatory affairs are a new profession that can be developed for the controlling the safety, quality and efficacy of the drug products by submitting the investigational new drug application (IND) and new drug application (NDA) to regulatory authority. The whole process may be done in conscious manner in order to release a safe drug product to protect the public from non-toxic effects of drugs during and after the usage of drugs. The main intention of this article was too aware the peoples towards the role of regulatory affairs department, requirements for new drug approval and the involvement of the regulatory professionals in this process access as well as how crucial it is to perform and monitor the clinical and nonclinical trials of the drug before marketing the drug.

🏷️ Keywords

Drug regulatory affairs MAA USFDA CDSCO EMA Notice of Compliance (NOC) Notice of Deficiency (NOD) RMS CMS ANDA

📚 How to Cite:

Mr. Anurag Shivanand Jaybhaye, Mr. Arshad Asif Ansari, Dr. Sunil S Jaybhaye , REVIEW ON DRUG REGULATORY AFFAIRS (DRA) AND NEW DRUG APPROVAL PROCESS , Volume 11 , Issue 12, December 2025, EPRA International Journal of Multidisciplinary Research (IJMR) , Pages: 135 - 139 ,

🔗 PDF URL

https://cdn.epratrustpublishing.com/article/1765613045518-23.EPRA JOURNALS 25236.pdf

📄 PDF Preview

Click the button above to load the PDF.